Vaccines for Enteric Diseases

9-11 October 2017, NAU Sao Rafael Atlantico Hotel, Albufeira, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Monday 9th October 2017

07.15 Onwards
Arrival & Registration & Poster Session A Set-Up

08.45-09.00
Welcome to VED 2017 & Opening Remarks
Richard Walker (PATH, Washington DC, USA)

SESSION 1:
BURDEN OF DISEASE

Moderator: Richard Walker (PATH, Washington DC, USA)

09.00-09.30
‘Changing the diarrheal disease narrative, now’

Eileen Quinn (PATH, Washington DC, USA)

09.30-10.00
‘Vaccine impact on diarrhea in Africa (VIDA) study of the incidence, etiology and adverse clinical consequences of moderate-to-severe diarrhea (MSD) in Sub-Saharan Africa following introduction of rotavirus vaccine’

Karen L. Kotloff (Center for Vaccine Development, Institute for Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA)

10.00-10.30
‘The global burden of diarrheal diseases: Results from the global burden of disease study 2016’
Christopher Troeger, Ibrahim Khalil, Puja Rao, Manny Garcia, Shijun Cao, Ali H. Mokdad, Simon Hay and Robert Reiner (Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA)

10.30-10.50
‘Etiology of diarrhea in hospitalized patients at the International Centre for Diarrhoeal Disease Research, Bangladesh from 2014-2016 using quantitative PCR’
Mami Taniuchi1, James Platts-Mills1, Abu Sayeed2, Farhana Khanam2, Ashraful Islam Khan2, Jie Liu1, Eric Houpt1 and Firdausi Qadri2 (1 Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, USA; 2 Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh)

10.50-11.20
Coffee Break & Poster Session A Set-Up

SESSION 2:
ETEC VACCINES I

Moderators: John Clements (Tulane University, New Orleans, Louisiana, USA) and Lou Bourgeois (PATH, Washington DC, USA)

11.20-11.40
‘Development of a recombinant CS6 based ETEC vaccine’

Michael Prouty1, Steven Poole1, Milton Maciel1, Yang Liu1, Amritha Ramakrishnan2, Annette McVeigh1, April Fordyce1, Nate Reynolds2, Mark Simons2, David Poncet3, Premkumar Dinadayala3, Sabrina Joseph1, Mark Riddle1, Jon Heinrichs3, Geneviève Renauld-Mongénie3 and Stephen Savarino1,3 (1 Naval Medical Research Center, Silver Spring, Maryland, US; 2 Naval Medical Research Unit Number Six, Lima, Peru; 3 Sanofi-Pasteur, Marcy l’Etoile, France and Swiftwater, Pennsylvania, USA)

11.40-12.00
‘Prevalence and molecular conservation of novel candidate antigens in a diverse population of Enterotoxigenic Escherichia coli isolates’
F. Matthew Kuhlmann1, Jie Ning1, Madeline Pashos1, John Martin2, Makedonka Mitreva1,2, Tracy H. Hazen3, David A. Rasko3, Felipe Del Canto4, Roberto Vidal4, Elizabeth Cebelinski5, Dave Boxrud5, Firdausi Qadri6 and James M. Fleckenstein1,7 (1 Department of Medicine, Division of Infectious Diseases, and the 2 McDonnell Genome Institute, Washington University, St. Louis, Missouri, USA; 3 The Department of Microbiology & Immunology, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA; 4 Universidad de Chile, Santiago, Chile; 5 Minnesota Department of Health, Molecular Epidemiology, Infectious Disease Laboratory, St. Paul, Minnesota, USA; 6 International Centre for Diarrhoeal Disease Research, Bangladesh, ICDDRB, Dhaka, Bangladesh; 7 Medicine Service, Veterans Affairs Medical Center, St. Louis, Missouri, USA)

12.00-12.20
‘Heat-stable enterotoxin (ST) cloaks ETEC from the host immune system and binds iron’
Mallory C. Kiefer, Carli C. Thompson, David L. Bauer, Elizabeth B. Norton, John D. Clements and Jacob P. Bitoun (Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA)

12.20-12.40
‘Passive immunity leads to enhanced priming of the immune system upon oral immunization with F4 fimbriae’
Ut V. Nguyen1, Bert Devriendt1, Bruno M. Goddeeris2 and Eric Cox1 (1 Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium; 2 Faculty of Bioscience Engineering, KU Leuven, Leuven, Belgium)

12.40-13.00
‘Novel structure-based MEFA (multiepitope fusion antigen) vaccinology for a vaccine candidate inducing antibodies against 15 adhesins of enterotoxigenic Escherichia coli (ETEC)’

Qiangde Duan1, Rahul Nandre1, Xiaosai Ruan1, David A. Sack2 and Weiping Zhang1 (1 Department of Diagnostic Medicine/Pathobiology, Kansas State University College of Veterinary Medicine, Manhattan, Kansas, USA; 2 Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA)

13.00-14.00
Lunch Break & Poster Session A

SESSION 3:
ETEC VACCINES II

Moderators: Ann-Mari Svennerholm (University of Gothenburg, Gothenburg, Sweden) and Richard Walker (PATH, Washington DC, USA)

14.00-14.10
‘ETEC and Shigella vaccine development: A priority for WHO’s Initiative for Vaccine Research’
Birgitte K. Giersing and Martin Friede (Initiative for Vaccine Research, Dept. of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland)

14.10-14.30
‘Re-establishment and use of the ETEC B7A CHIM to assess the efficacy of orally administered bovine serum antibodies against CS6 or whole cell B7A’
Kawsar Talaat1, A. Louis Bourgeois1, Christopher Duplessis2, Chad K. Porter2, Milton Maciel Jr.2, Ramiro Gutierrez2, Barbara DeNearing1, Brittany Adjoodani1, Rachel Adkinson1, Kayla Jaep2, Brittany Feijoo1, Jessica Brubaker1, Aleksandra Beselman3, Subhra Chakraborty1, David Sack1, Jane Halpern1, Stefanie Trop2, Mark Riddle2, Sabrina Joseph2, Steven Poole2 and Michael Prouty2
(1 Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore MD; 2 Naval Medical Research Center, Silver Spring, MD; 3 Johns Hopkins Bayview Medical Center, Baltimore, MD)

14.30-14.50
‘Optimizing LT antibody analyses to predict protection from oral H10407 ETEC challenge’
Milton Maciel Jr.1, Robin Baudier2, Eduardo Valli2, Clarissa D. Mulloy2, Chad Porter1, Ramiro Gutierrez1, John Clements2 and Elizabeth Norton2 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Tulane University, New Orleans, Louisiana, USA)

14.50-15.10
‘Immunological factors contributing to enhanced protective efficacy in volunteers immunized with the dmLT adjuvanted ACE 527 ETEC vaccine’
Subhra Chakraborty1, Clayton Harro1, Jessica Brubaker1, Barbara DeNearing1, Nicole Bauers2, Len Dally3, Alan Fix2, Sachin Mani2, Louis Bourgeois1,2, Richard Walker2 and David Sack1 (1 The Johns Hopkins Bloomberg School of Public Health,Baltimore, Maryland, USA; 2 PATH, Washington DC, USA; 3 EMMES Corporation, Rockville, Maryland, USA)

15.10-15.30
‘A Phase I/II trial of the oral inactivated ETEC Vaccine (ETVAX; OEV 122) in descending age groups in Bangladesh’
Firdausi Qadri, Mohiul Islam Chowdhury1, Taufiqur Rahman Bhuiyan1, Farhana Khanam1, Tasnuva Ahmed1, Marjahan Akhtar1, Anna Lundgren2, Richard Walker3, Lou Bourgeois3, Alan Fix3, Tom Wierzba3 and Ann-Mari Svennerholm2 (1 ICDDRB, Dhaka, Bangladesh; 2 University of Gothenburg, Gothenburg, Sweden; 3 PATH, Washington DC, USA)

15.30-15.50
‘OEV-123 – a clinical trial on ETVAX, an oral vaccine against enterotoxigenic escherichia coli diarrhea’
Anu Kantele (University of Helsinki and Helsinki University Hospital, Helsinki, Finland)

15.50-16.10
Tea Break & Poster Session A

SESSION 4:
NOROVIRUS VACCINES

Moderator: Robert Bargatze (Takeda Vaccines Inc., Bozeman, Montana, USA)

16.10-16.40
‘Progress towards a norovirus vaccine’
Timo Vesikari (University of Tampere, Tampere, Finland)

16.40-17.00
‘A phase 1 randomized, placebo controlled trial for the prevention of norovirus illness using an oral recombinant adenoviral based vaccine’
Leesun Kim, Karen Lin, Kassandra Kasparek, Keith Gottlieb, Dave Liebowitz and Sean Tucker (Vaxart Inc., South San Francisco, California, USA)

17.00-17.20
‘Updated estimates of the global burden of norovirus disease’
Aron J. Hall1,2, Sara M. Pires3, Brecht Devleesschauwer4, Anita Kambhampati1,5, Kayoko Shioda1,5, Sharia M. Ahmed1,5, Anne Robinson1,2, Linda Verhoef6, Umesh Parashar1, Ben Lopman1,2 and Marion Koopmans6,7 (1 Centers for Disease Control and Prevention, Atlanta, Georgia, USA; 2 Emory University, Atlanta, Georgia, USA; 3 Danish Technical University, Lyngby, Denmark; 4 University of Ghent, Ghent, Belgium; 5 Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA; 6 National Institute for Public Health and the Environment, Bilthoven, The Netherlands; 7 Viroscience Department, ErasmusMC, Rotterdam, The Netherlands)

17.20-17.40
‘Immunotypes: A genomics approach to understand norovirus immunity’
Gabriel I. Parra (Division of Viral Products, CBER, FDA, Silver Spring, Maryland, USA)

17.40-18.00
‘The burden of medically attended acute gastro-enteritis due to norovirus in Japan: Results from a database analysis’
C. Chang1, M. Sakaguchi1, T. Verstraeten2 and J. Weil3 (1 Takeda Pharmaceutical Company, Osaka, Japan; 2 P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium; 3 Takeda Vaccines Inc., Bozeman, Illinois, USA)

18.00-18.20
‘Replication of human norovirus in human intestinal enteroids’
Jan Vinjé1, Esther K. Morantz2, Hannah Browne3, Khalil Ettayebi4, Xi-Lei Zeng4, Mary K Estes4 and Veronica Costantini1 (1 Centers for Disease Control, Atlanta, Georgia, USA; 2 Synergy America Inc, Atlanta, Georgia, USA; 3 Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA; 4 Baylor College of Medicine, Houston, Texas, USA)

18.20-19.30
VED 2017 Welcome Drinks Reception & VED 2017 Poster Session A

 

VED 2017 Delegates

Login details will be supplied after you have registered for the event.


VED 2017 Sponsors

  • Sanofi Pasteur
  • LimmaTech
  • Takeda
  • BioVAXX
  • Vaxart
  • VisMederi
  • Eveliqure
  • PATH
  • DNAvaccine.com
  • Matrivax
  • Vaccine Research Center
  • hVIVO
  • Aldevron
  • NatureGeneTherapy.com

VED 2017 Downloads

VED 2017 Leaflet

VED 2017 Mailing List

Name
E-mail Address
What is 3+2-1?